Barclays PLC upgraded shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) from an equal weight rating to an overweight rating in a report published on Tuesday. They currently have $155.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $150.00.

Other equities analysts also recently issued reports about the stock. Piper Jaffray Cos. set a $176.00 price objective on shares of Alexion Pharmaceuticals and gave the company a buy rating in a report on Sunday, November 6th. Vetr downgraded shares of Alexion Pharmaceuticals from a strong-buy rating to a buy rating and set a $150.62 price objective on the stock. in a report on Wednesday, August 3rd. Jefferies Group reaffirmed a hold rating on shares of Alexion Pharmaceuticals in a report on Tuesday, August 9th. Credit Suisse Group AG reaffirmed a buy rating and set a $165.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, November 7th. Finally, Wedbush increased their price objective on shares of Alexion Pharmaceuticals from $132.00 to $135.00 and gave the company a neutral rating in a report on Friday, October 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $173.59.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 125.59 on Tuesday. The stock has a market capitalization of $28.15 billion, a PE ratio of 76.58 and a beta of 1.45. The company’s 50 day moving average is $122.56 and its 200-day moving average is $128.72. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm had revenue of $799 million for the quarter, compared to the consensus estimate of $787.07 million. During the same period in the prior year, the firm posted $1.16 earnings per share. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. Analysts forecast that Alexion Pharmaceuticals will post $4.64 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals Inc. (ALXN) Upgraded to “Overweight” by Barclays PLC” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. and international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/alexion-pharmaceuticals-inc-alxn-upgraded-to-overweight-by-barclays-plc.html.

In related news, EVP Julie O’neill sold 650 shares of the business’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $126.29, for a total value of $82,088.50. Following the sale, the executive vice president now directly owns 35,384 shares in the company, valued at approximately $4,468,645.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Leonard Bell sold 37,317 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the completion of the sale, the director now owns 440,936 shares in the company, valued at $61,898,595.68. The disclosure for this sale can be found here. 4.41% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. raised its stake in Alexion Pharmaceuticals by 27.5% in the third quarter. D.A. Davidson & CO. now owns 1,578 shares of the biopharmaceutical company’s stock valued at $191,000 after buying an additional 340 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new stake in Alexion Pharmaceuticals during the third quarter valued at approximately $5,475,000. LPL Financial LLC raised its stake in Alexion Pharmaceuticals by 75.2% in the third quarter. LPL Financial LLC now owns 24,556 shares of the biopharmaceutical company’s stock valued at $3,030,000 after buying an additional 10,540 shares in the last quarter. Credit Suisse AG raised its stake in Alexion Pharmaceuticals by 3.1% in the third quarter. Credit Suisse AG now owns 596,567 shares of the biopharmaceutical company’s stock valued at $73,102,000 after buying an additional 17,715 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in Alexion Pharmaceuticals by 12.0% in the third quarter. Ameritas Investment Partners Inc. now owns 9,388 shares of the biopharmaceutical company’s stock valued at $1,150,000 after buying an additional 1,005 shares in the last quarter. Institutional investors and hedge funds own 94.85% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.